Kaitlyn D’Onofrio

DocwireNews

Insulin use in the treatment of type 2 diabetes could go up by more than 20% by 2030, according to a new analysis.&nbsp;Using information from the International Diabetes Federation and 14 cohort studies, researchers created a microsimulation of the burden associated with type 2 diabetes from 2018 to 2030 in 221 countries. They predicted how many people with type 2 diabetes would likely use insulin, how many international units (IU) would be required, and&nbsp;disability-adjusted life-years (DALYs)&nbsp;averted annually with alternative treatment algorithms aimed at&nbsp;HbA1c&nbsp;from 6.5% to 8%, lower microvascular risk, or higher HbA1c&nbsp;for those aged 75 years and older.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Half of people worldwide who need <a href="https://twitter.com/hashtag/insulin?src=hash&amp;ref_src=twsrc%5Etfw">#insulin</a> to treat type 2 <a href="https://twitter.com/hashtag/diabetes?src=hash&amp;ref_src=twsrc%5Etfw">#diabetes</a> will not receive it in 2030 unless access is improved&mdash;finding from a microsimulation analysis <a href="https://twitter.com/TheLancetEndo?ref_src=twsrc%5Etfw">@TheLancetEndo</a> <a href="https://t.co/kMGgtU1eVP">https://t.co/kMGgtU1eVP</a> <a href="https://t.co/1UIcRQRjqG">pic.twitter.com/1UIcRQRjqG</a>
&mdash; The Lancet (@TheLancet) <a href="https://twitter.com/TheLancet/status/1065172023276654592?ref_src=twsrc%5Etfw">November 21, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The researchers estimate that the number of type 2 diabetes patients worldwide will increase from 405.6 million&nbsp;(95% CI 315.3 million&ndash;533.7 million) in 2018 to 510.8 million (395.9&nbsp;million&ndash;674.3&nbsp;million) in 2030.&nbsp;Based on these figures, they predict annual insulin use across the globe will jump from&nbsp;516.1 million 1,000 IU vials (95% CI 409.0 million&ndash;658.6 million) in 2018 to 633.7 million (500.5 million&ndash;806.7 million) in 2030.&nbsp;Insulin accessibility will also play a large role. If access does not get better, 7.4% (95% CI 5.8&ndash;9.4) of all type 2 diabetes patients in 2030 will use insulin, but if accessibility improves&nbsp;and&nbsp;insulin is&nbsp;prescribed to achieve an HbA1c&nbsp;of 7% (53 mmol/mol) or lower, the number of patients receiving insulin will more than double to 15.5% (12.0&ndash;20.3). If all type 2 diabetes patients achieve&nbsp;HbA1c&nbsp;of 7%&nbsp;or lower, by 2030, insulin would avert 331,101 DALYs each year (95% CI 256,601&ndash;437,053). The researchers also predict that accessibility to new oral&nbsp;antihyperglycaemic&nbsp;drugs would avert DALYs by 14.9%, and averted DALYs would increase by 44.2% if patients aged 75 years and older had a target&nbsp;HbA1c&nbsp;of 8% (64 mmol/mol)&nbsp;due to reduced&nbsp;hypoglycaemia.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
40 million people with diabetes will be left without insulin by 2030, a new study predicts <a href="https://t.co/aJbw547VIS">https://t.co/aJbw547VIS</a> <a href="https://t.co/RhkPZRk3Nq">pic.twitter.com/RhkPZRk3Nq</a>
&mdash; CNN International (@cnni) <a href="https://twitter.com/cnni/status/1065273982444802051?ref_src=twsrc%5Etfw">November 21, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The study authors concluded, &ldquo;The insulin required to treat type 2 diabetes is expected to increase by more than 20% from 2018 to 2030. More DALYs might be averted if&nbsp;HbA&nbsp;1c targets are higher for older adults.&rdquo;&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/coffee-consumption-type-2-diabetes-risk/">Coffee Consumption Associated with Reduced Type 2 Diabetes Risk</a>&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/prevalence-of-diagnosed-type-1-and-type-2-diabetes-among-us-adults-in-2016-and-2017-population-based-study/">Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population- based study</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/fda-canagliflozin-type-2-diabetes/">FDA Approves Type 2 Diabetes Treatment to Help Prevent Cardiovascular Risks</a>&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/type-2-diabetes-population-based/">Impact of age at appendectomy on development of type 2 diabetes: A population-based cohort study</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/whole-grains-type-2-diabetes/">Whole Grains Tied to Decrease in Type 2 Diabetes</a>&nbsp;Source:&nbsp;<a href="https://www.thelancet.com/journals/landia/article/PIIS2213-8587(18)30303-6/fulltext">The Lancet Diabetes &amp; Endocrinology</a>

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Study Forecasts Increase in Insulin Use for Type 2 Diabetes by 2030

Diabetes

Insulin use in the treatment of type 2 diabetes could go up by more than 20% by 2030, according to a new analysis.  ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe